Arcellx, Inc.
Business
Arcellx is a clinical-stage biotechnology company developing immunotherapies using its proprietary D-Domain technology platform, which enhances chimeric antigen receptor (CAR) T-cell therapies. The company's lead programs include anito-cel (a ddCAR therapy for multiple myeloma) and ARC-SparX modular CAR-T platform candidates targeting various hematologic malignancies, solid tumors, and autoimmune diseases. Arcellx collaborates with Kite Pharma (Gilead) on anito-cel development and commercialization, while retaining worldwide rights to other programs; the company is pursuing FDA approval for anito-cel in relapsed/refractory multiple myeloma and has pending acquisition by Gilead.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue from related party | 22 | 108 | 110 | — | — | |
| Research and development | 158 | 157 | 134 | 150 | 47 | |
| General and administrative | 118 | 88 | 66 | 42 | 18 | |
| Total operating expenses | 275 | 246 | 200 | 191 | 65 | |
| Loss from operations | −253 | −138 | −90 | −191 | −65 | |
| Interest and other income (expense) | 24 | 33 | 24 | 4 | — | |
| Interest expense | 0 | −1 | −4 | −2 | −10,000 | |
| Total other income, net | 24 | 32 | 20 | 3 | 49,000 | |
| Loss before income taxes | −229 | −105 | −70 | −189 | — | |
| Income tax expense | −69,000 | −2 | −663,000 | — | — | |
| Net loss | −229 | −107 | −71 | −189 | −65 | |
| Unrealized gain (loss) on marketable securities | −5,000 | 301,000 | 768,000 | −201,000 | 20,000 | |
| Comprehensive loss | −229 | −107 | −70 | −189 | −65 | |
| Net loss per share attributable to common stockholders - basic | −4.07 | −2 | −1.47 | −5.19 | −145.55 | |
| Net loss per share attributable to common stockholders - diluted | −4.07 | −2 | −1.47 | −5.19 | −145.55 | |
| Weighted-average common shares outstanding - basic | 56 | 54 | 48 | 36 | 446,379 | |
| Weighted-average common shares outstanding - diluted | 56 | 54 | 48 | 36 | 446,379 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 80 | 106 | 395 | 64 | 31 | |
| Marketable securities | 370 | 482 | 307 | 191 | 74 | |
| Restricted cash, current | 0 | 208,000 | 2 | 0 | — | |
| Prepaid expenses and other current assets | 12 | 12 | 12 | 12 | 8 | |
| Total current assets | 462 | 599 | 716 | 267 | 113 | |
| Restricted cash, non-current | 3 | 2 | 2 | 3 | 199,000 | |
| Marketable securities, non-current | 70 | 38 | 27 | 0 | — | |
| Property and equipment, net | 43 | 46 | 43 | 11 | 10 | |
| Operating lease right-of-use assets | 24 | 24 | 27 | 29 | 3 | |
| Prepaid research and development expenses and other long-term assets | 3 | 1 | 9 | 5 | 2 | |
| Total assets | 604 | 711 | 825 | 314 | 129 | |
| Accounts payable | 6 | 2 | 3 | 9 | 1 | |
| Accrued liabilities | 35 | 57 | 18 | 12 | 13 | |
| Operating lease liabilities, current portion | 8 | 7 | 8 | 3 | — | |
| Finance lease liabilities, current portion | 0 | 230,000 | 39 | 33 | — | |
| Contract liability to related party | 56 | 59 | 51 | — | — | |
| Total current liabilities | 104 | 125 | 118 | 57 | 15 | |
| Operating lease liabilities, net of current portion | 44 | 47 | 51 | 31 | — | |
| Contract liabilities, net of current portion to related party | 53 | 76 | 171 | 0 | — | |
| Other non-current liabilities | 0 | 9 | — | — | 178,000 | |
| Total liabilities | 202 | 257 | 340 | 109 | 17 | |
| Commitments and Contingencies (Note 11) | — | — | — | — | — | |
| Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 57,929,325 shares issued and outstanding as of December 31, 2025; 1,000,000,000 shares authorized and 54,293,597 shares issued and outstanding as of December 31, 2024 | 56,000 | 53,000 | 52,000 | 44,000 | 1,000 | |
| Additional paid-in capital | 1,127 | 951 | 874 | 524 | 9 | |
| Accumulated other comprehensive income | 843,000 | 848,000 | 547,000 | −221,000 | −20,000 | |
| Accumulated Deficit | −726 | −497 | −389 | −319 | −130 | |
| Total stockholders' equity | 402 | 455 | 485 | −205 | −122 | |
| Total liabilities and stockholders' equity | 604 | 711 | 825 | 314 | 129 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 7 | 5 | 2 | 1 | 1 | |
| Loss on disposal of property and equipment | 82,000 | −260,000 | 174,000 | 3,000 | 3,000 | |
| Noncash operating lease expense | −38,000 | 3 | 1 | — | — | |
| Right of use asset expensed | 0 | 794,000 | 19 | 63 | — | |
| Amortization of premiums and discounts on marketable securities | −8 | −15 | −11 | −2 | 210,000 | |
| Share-based compensation | 78 | 61 | 42 | 22 | 7 | |
| Prepaid expenses and other current and non-current assets | −2 | 9 | −8 | −6 | −6 | |
| Accounts payable and other current liabilities | 3 | −70,000 | −6 | 7 | 974,000 | |
| Accrued liabilities | −21 | 42 | 6 | −395,000 | 8 | |
| Operating lease liabilities | −2 | −4 | 13 | 3 | — | |
| Contract liability to related party | −26 | −86 | 221 | — | — | |
| Other non-current liabilities | −9 | 9 | 0 | — | — | |
| Net cash provided by (used in) operating activities | −210 | −83 | 208 | −99 | −54 | |
| Purchases of property and equipment | −2 | −13 | −21 | −2 | −6 | |
| Purchases of marketable securities | −407 | −597 | −442 | −274 | −74 | |
| Proceeds from maturities of marketable securities | 496 | 428 | 309 | 158 | — | |
| Net cash provided by (used in) investing activities | 86 | −183 | −155 | −118 | −80 | |
| Proceeds from issuance of common stock in private placement, net of transactions costs | 0 | 0 | 300 | 10 | — | |
| Proceeds from issuance of common stock in offerings, net of issuance costs | 132 | 0 | 0 | 129 | — | |
| Proceeds from exercise of stock options | 4 | 15 | 8 | — | — | |
| Proceeds from issuance of common stock under the employee stock purchase plan | 1 | 1 | 1 | — | — | |
| Payments under finance leases | −230,000 | −40 | −29 | −10 | — | |
| Tax withholding payments related to net share settlement of restricted stock units | −38 | 0 | 0 | — | — | |
| Net cash provided by (used in) financing activities | 99 | −24 | 279 | 253 | 118 | |
| Net increase (decrease) in cash and cash equivalents and restricted cash | −25 | −291 | 332 | 36 | −16 | |
| Cash paid for income taxes | 1 | 2 | 212,000 | — | — | |
| Purchase of property and equipment included in accounts payable and accrued liabilities | 944,000 | 325,000 | 2 | 770,000 | 278,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Arcellx, Inc.'s CIK number?
Arcellx, Inc.'s SEC CIK number is 0001786205 (1786205). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Arcellx, Inc.'s SEC filings?
All of Arcellx, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Arcellx, Inc. last report earnings?
Arcellx, Inc. (ACLX) most recently filed an earnings 8-K with the SEC on Nov 5, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-25-266866). This is Arcellx, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Arcellx, Inc.'s most recent earnings 8-K?
Arcellx, Inc.'s latest earnings 8-K (Item 2.02) was filed Nov 5, 2025 under accession 0001193125-25-266866. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Arcellx, Inc.'s latest earnings 8-K →
Look up any company's CIK number →